Johnson & Johnson expands DARZALEX FASPRO label with new D-VRd approval in newly diagnosed myeloma
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.